Back to search results

Research Study for Zenagamtide vs. Semaglutide for Excess Body Weight

This study is looking into how well a medicine called Zenagamtide helps people with excess body weight lose weight, compared to another medicine called Semaglutide. We want to see if Zenagamtide is safe and effective. Participants will receive either Zenagamtide, Semaglutide, or a placebo (an inactive substance that looks like the study medicine) through injections under the skin. The main goal is to measure the change in body weight over 84 weeks. You might be able to join if you are 18 years or older and have excess body weight, but do not have diabetes. The study aims to enroll about 650 people, but its current status is unclear.

Study design
This is an interventional study comparing Zenagamtide, Semaglutide, and placebos. It plans to enroll about 650 participants.
What's involved
Participants will receive subcutaneous injections of Zenagamtide, Semaglutide, or a placebo. The primary endpoint is measured from week 0 to week 84.
Compensation
Not stated in the trial record.
Follow-up
Body weight will be measured from week 0 to week 84.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07668414

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatment
Novo Nordisk A/S
~650 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:ZenagamtideSemaglutidePlacebo (matched to semaglutide)Placebo (matched to zenagamtide)

At a glance

Recruiting sites
0 of 43 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relative change in body weight
Measured over From week 0 to week 84

Conditions

Overweight
Obesity

Explore related trials

ObesityOverweight

Where it's being run

43 sites across 15 states
Florida10
Texas10
California4
South Carolina3
Georgia2
Illinois2
New York2
Virginia2

Study leadership

  • Clinical Transparency (dept. 2834) · STUDY_DIRECTOR · Novo Nordisk A/S

Who to contact

Novo Nordisk
[email protected]
(+1) 866-867-7178
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female (sex at birth).
Age 18 years or above at the time of signing the informed consent.

Exclusion

Glycated haemoglobin (HbA1c) ≥ 6.5% (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening.
History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues within 1 year before screening.

What this trial measures

  • Relative change in body weightFrom week 0 to week 84

    Measured as percentage (%) change in body weight.